NCT04365153 - Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

February 2, 2021

Study Completion Date

April 1, 2021

Conditions

COVID-19SARS-CoV 2

Interventions

DRUG

Canakinumab Injection 600mg

Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours

DRUG

Canakinumab Injection 300mg

Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours

DRUG

Placebos

250 mL of 5% dextrose infused IV over 2 hours

Trial Locations (2)

33331

Cleveland Clinic Florida, Weston

44195

Cleveland Clinic, Cleveland